Critical Contrast: Telomir Pharmaceuticals (TELO) vs. Its Rivals

Telomir Pharmaceuticals (NASDAQ:TELO) is one of 1,069 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Telomir Pharmaceuticals to similar businesses based on the strength of its profitability, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

Insider & Institutional Ownership

44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.6% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Telomir Pharmaceuticals and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	-$16.53 million	-7.81
Telomir Pharmaceuticals Competitors	$9.93 billion	$136.87 million	-7.77

Telomir Pharmaceuticals’ competitors have higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Telomir Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-1,170.58%	-832.67%
Telomir Pharmaceuticals Competitors	-3,399.87%	-235.11%	-32.77%

Analyst Recommendations

This is a summary of current ratings and price targets for Telomir Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0	0	1	1	3.50
Telomir Pharmaceuticals Competitors	8323	22118	50203	1341	2.54

Telomir Pharmaceuticals presently has a consensus target price of $15.00, suggesting a potential upside of 231.13%. As a group, “Pharmaceutical preparations” companies have a potential upside of 202.19%. Given Telomir Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Telomir Pharmaceuticals is more favorable than its competitors.

Summary

Telomir Pharmaceuticals competitors beat Telomir Pharmaceuticals on 8 of the 12 factors compared.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.